Concepedia

Shuji Murakami

SM

90

Publications

14.6K

Citations

35

H-Index

1983

Active since

Affiliations

Kanagawa Prefectural Hospital Organization(Current)

Kanagawa Cancer Center

Yokohama City University

AstraZeneca (United Kingdom)

Moffitt Cancer Center

Shuji Murakami is an author at Kanagawa Prefectural Hospital Organization specializing in medicine, lung cancer, and oncology.

ORCID

Top concepts

Publications per year

1983–2025

90

Publications

90

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.4K citations · Full text

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

, , +5

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

Jhanelle E. Gray, Augusto Villegas, Davey B. Daniel et al. · Journal of Thoracic Oncology · 2019 · 423 citations · Full text

Rows per page

1–5 of 90